Tenaya Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for TN-401
Tenaya Therapeutics, a clinical-stage biotechnology company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for its gene therapy candidate, TN-401. This designation is for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a serious heart disease. The RMAT designation is an expedited program designed to facilitate the development and review of regenerative medicine therapies for severe conditions where preliminary clinical evidence suggests the potential to address unmet medical needs. Tenaya's RMAT application included data from the RIDGE-1 clinical trial, which showed improvements in electrical stability measures, such as reduced rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs), common forms of ventricular arrhythmias in ARVC. The company's CEO, Faraz Ali, highlighted that this designation underscores the recognition of the seriousness of PK...
